Buy Rating Affirmed for 2seventy bio Despite Trial Setback: Niche Market Strategy and Safety Profile Underpin Positive Outlook
Daina Graybosch, an analyst from Leerink Partners, reiterated the Buy rating on 2seventy bio (TSVT – Research Report). The associated ...
2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue Performance
CAMBRIDGE, Mass., September 25, 2024--2seventy bio, Inc. (Nasdaq: TSVT) today announced that the Company, in partnership with ...
FiercePharma2d
Citing enrollment challenges, Bristol Myers and 2seventy scrap Abecma trial in first-line myeloma
Bristol Myers Squibb’s struggling CAR-T therapy Abecma has hit a major setback. | Bristol Myers Squibb’s CAR-T therapy Abecma ...
Pharmabiz20h
Bristol Myers Squibb, 2seventy bio to discontinue enrollment in phase 3 KarMMa-9 study of Abecma in patients with newly diagnosed MM
Bristol Myers Squibb, 2seventy bio to discontinue enrollment in phase 3 KarMMa-9 study of Abecma in patients with newly diagnosed MM: Princeton, New Jersey Friday, September 27, 2 ...
Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability
KarMMa-9 trial for Abecma, saving $80 million and focusing on profitability by 2025. Despite the decision, the company ...
MedPage Today2d
Cancer Treatment Ups CV Risk; Therapy's Next Big Thing; Nude Photos Settlement
(Endpoints News) Bristol Myers Squibb and 2seventy bio announced discontinuation of enrollment in the phase III KarMMa-9 ...
The Pharma Letter2d
2seventy bio and BMS to drop KarMMa-9 study
US biotech 2seventy bio and partner Bristol Myers Squibb today revealed that they will discontinue enrollment in its ongoing ...
Hold Rating on 2seventy bio Amidst Strategic Shifts and Enrollment Challenges
In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on 2seventy bio (TSVT – Research Report), with a ...
BioPharma Dive2d
Struggling 2Seventy scraps a key cancer study
The biotech expects that stopping enrollment for KarMMa-9, a trial evaluating early use of the multiple myeloma cell therapy Abecma, should save it $80 million in the near term.